tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DE:VX1 Stock Latest News

Vertex Pharmaceuticals Signals Confident Growth Beyond CF
Company AnnouncementsVertex Pharmaceuticals Signals Confident Growth Beyond CF
2d ago
VRTX
Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $570 from $564 at Morgan Stanley
3d ago
VRTX
Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank
3d ago
VRTX
Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $541 from $546 at RBC Capital
3d ago
VRTX
Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
3d ago
VRTX
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
PremiumThe FlyCrispr Therapeutics price target raised to $74 from $62 at Evercore ISI
3d ago
CRSP
VRTX
Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald
Premium
The Fly
Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald
3d ago
VRTX
Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex
Premium
Ratings
Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex
3d ago
VRTX
Vertex Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
PremiumThe Fly
Vertex Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
3d ago
VRTX
Vertex Pharmaceuticals price target raised to $466 from $445 at Stifel
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $466 from $445 at Stifel
3d ago
VRTX
Vertex Pharmaceuticals price target raised to $518 from $478 at H.C. Wainwright
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $518 from $478 at H.C. Wainwright
3d ago
VRTX
Vertex Pharmaceuticals reports Q4 adjusted EPS $5.03, consensus $5.15
PremiumThe Fly
Vertex Pharmaceuticals reports Q4 adjusted EPS $5.03, consensus $5.15
4d ago
VRTX
Vertex Pharmaceuticals sees FY26 revenue $12.95B-$13.1B, consensus $13B
PremiumThe FlyVertex Pharmaceuticals sees FY26 revenue $12.95B-$13.1B, consensus $13B
4d ago
VRTX
Notable companies reporting after market close
Premium
The Fly
Notable companies reporting after market close
4d ago
ABNB
AMAT
Vertex Pharmaceuticals’ povetacicept granted FDA orphan designation
Premium
The Fly
Vertex Pharmaceuticals’ povetacicept granted FDA orphan designation
6d ago
VRTX
Is VRTX a Buy, Before Earnings?
PremiumPre-Earnings
Is VRTX a Buy, Before Earnings?
6d ago
VRTX
Vertex Pharmaceuticals, WuXi Biologics enter license and research service pact
PremiumThe Fly
Vertex Pharmaceuticals, WuXi Biologics enter license and research service pact
13d ago
VRTX
Vertex Pharmaceuticals: Positive Risk-Reward on Emerging Renal Pipeline and Pove IgAN Phase 3 Catalyst Supports Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Positive Risk-Reward on Emerging Renal Pipeline and Pove IgAN Phase 3 Catalyst Supports Buy Rating
17d ago
VRTX
Vertex Pharmaceuticals assumed with Overweight from Equal Weight at Barclays
PremiumThe Fly
Vertex Pharmaceuticals assumed with Overweight from Equal Weight at Barclays
20d ago
VRTX
Vertex Pharmaceuticals price target raised to $545 from $535 at UBS
PremiumThe FlyVertex Pharmaceuticals price target raised to $545 from $535 at UBS
21d ago
VRTX
Vertex Pharmaceuticals price target raised to $530 from $475 at Evercore ISI
Premium
The Fly
Vertex Pharmaceuticals price target raised to $530 from $475 at Evercore ISI
24d ago
VRTX
Vertex Pharmaceuticals gets orphan status for membranous nephropathy treatment
Premium
The Fly
Vertex Pharmaceuticals gets orphan status for membranous nephropathy treatment
25d ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >